[Federal Register Volume 69, Number 61 (Tuesday, March 30, 2004)]
[Notices]
[Page 16582]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-6974]



[[Page 16582]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Nonprescription Drugs Advisory Committee and the Dermatologic and 
Ophthalmic Drugs Advisory Committee; Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Nonprescription Drugs Advisory Committee and the 
Dermatologic and Ophthalmic Drugs Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 6, 2004, from 8 a.m. 
to 5:30 p.m. and May 7, 2004, from 8 a.m. to 11 a.m.
    Location: Center for Drug Evaluation and Research Advisory 
Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville, MD.
    Contact Person: Karen Templeton-Somers or Kimberly Littleton 
Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug 
Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers 
Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, e-mail: 
[email protected] or [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), codes 3014512541 or 3014512534. Please call the Information Line 
for up-to-date information on this meeting. The background materials 
for this meeting will become available no later than 1 business day 
before the meeting and will be posted at www.fda.gov/ohrms/dockets/ac/acmenu.htm. (Click on the year 2004 and scroll down to the 
Nonprescription Drugs Advisory Committee or the Dermatologic and 
Ophthalmic Drugs Advisory Committee).
    Agenda: On both days, the committee will discuss efficacy and 
labeling issues for over-the-counter drug products used in the 
treatment of tinea pedis (interdigital) in patients 12 years of age and 
over.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by April 23, 
2004. Oral presentations from the public will be scheduled between 
approximately 1 p.m. and 2 p.m. on May 6, 2004. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before April 23, 2004, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Karen Templeton-
Somers or Kimberly Littleton Topper at least 7 days in advance of the 
meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: March 22, 2004.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 04-6974 Filed 3-29-04; 8:45 am]
BILLING CODE 4160-01-S